Stoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Stoke Therapeutics (NASDAQ:STOK) posted its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38, Zacks reports. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $9.00 on Tuesday. Stoke Therapeutics has a fifty-two week low of $5.60 and a fifty-two week high of $17.58. The firm has a market cap of $476.70 million, a PE ratio of -4.29 and a beta of 0.99. The business has a 50 day moving average price of $9.53 and a 200-day moving average price of $11.58.

Wall Street Analyst Weigh In

STOK has been the subject of several research analyst reports. HC Wainwright lifted their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. Finally, Chardan Capital reissued a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics has an average rating of “Buy” and a consensus target price of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.